• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[多动症儿童的医学治疗:关于法国市场上销售的哌甲酯新剂型]

[Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].

作者信息

Le Heuzey M-F, Vergnaud S, Mouren M-C

机构信息

Service de psychopathologie de l'enfant et de l'adolescent, hôpital Robert-Debré, 48, boulevard Sérurier, 75935 Paris cedex 19, France.

出版信息

Arch Pediatr. 2006 Jan;13(1):100-3. doi: 10.1016/j.arcped.2005.09.007. Epub 2005 Oct 18.

DOI:10.1016/j.arcped.2005.09.007
PMID:16239100
Abstract

Multimodal treatment of hyperactive child includes psychostimulant medication, methylphenidate (MPH) marketed in France in its short-acting form since about ten years. We report our clinical experience about the first fifty methylphenidate responders who received one of the two sustained-release forms available since summer 2004, tablets of oros-methyphenidate (Concerta LP) or microgranule-filled capsules (Ritaline LP).

摘要

对多动儿童的多模式治疗包括使用精神振奋药物,自大约十年前以来,哌甲酯(MPH)以短效形式在法国上市。我们报告了关于首批五十名哌甲酯反应者的临床经验,这些患者自2004年夏季以来接受了两种缓释剂型之一的治疗,即奥罗哌甲酯片(专注达长效片)或微颗粒填充胶囊(利他林长效胶囊)。

相似文献

1
[Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].[多动症儿童的医学治疗:关于法国市场上销售的哌甲酯新剂型]
Arch Pediatr. 2006 Jan;13(1):100-3. doi: 10.1016/j.arcped.2005.09.007. Epub 2005 Oct 18.
2
Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.缓释哌甲酯:新制剂。新剂型:对少数儿童有轻微优势。
Prescrire Int. 2004 Dec;13(74):203-6.
3
Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.在三种注意缺陷多动障碍(ADHD)亚型中,对于速释型哌甲酯依从性差的患者,渗透型口服系统哌甲酯疗效更佳。
Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.
4
Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.与缓释混合安非他明盐相比,使用盐酸哌甲酯控释片进行兴奋剂治疗对改善患有注意力缺陷多动障碍的青少年驾驶员驾驶性能的相对益处。
Pediatrics. 2006 Sep;118(3):e704-10. doi: 10.1542/peds.2005-2947.
5
Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation.注意缺陷多动障碍患者服用缓释哌甲酯(利他林)的临床和认知反应:疗效评估。
Adv Ther. 2009 Dec;26(12):1097-110. doi: 10.1007/s12325-009-0083-9. Epub 2010 Jan 16.
6
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.OROS 哌甲酯治疗成人注意力缺陷/多动障碍的疗效与安全性:一项随机、安慰剂对照、双盲、平行组、剂量递增研究。
J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.
7
Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial.OROS® 甲基苯丙胺(专注达®)对注意缺陷多动障碍儿童和青少年的功能、疾病严重程度及生活质量的耐受性和影响:一项前瞻性非干预性试验的结果
Atten Defic Hyperact Disord. 2009 Dec;1(2):175-86. doi: 10.1007/s12402-009-0010-6. Epub 2009 Aug 6.
8
Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.用于注意力缺陷/多动障碍的哌甲酯治疗的连续性。
Arch Pediatr Adolesc Med. 2005 Jun;159(6):572-8. doi: 10.1001/archpedi.159.6.572.
9
Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.控释型哌甲酯能否改善核心症状及执行功能缺陷?针对成人注意力缺陷多动障碍的开放标签试验结果
Curr Med Res Opin. 2006 Dec;22(12):2557-66. doi: 10.1185/030079906X154132.
10
Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.将速释型哌甲酯转换为控释型哌甲酯治疗注意缺陷多动障碍儿童和青少年。
Eur Rev Med Pharmacol Sci. 2013 Sep;17(17):2345-9.